Annamycin liposomal

Drug Profile

Annamycin liposomal

Alternative Names: Annamycin liposomal - University of Texas M.D. Anderson Cancer Center; Annamycin-LF; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNA

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Aronex Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Cancer; Chronic myeloid leukaemia

Most Recent Events

  • 22 Mar 2017 Annamycin liposomal receives Orphan Drug status for Acute myeloid leukaemia (Second-line therapy or greater) in USA
  • 18 Nov 2016 Moleculin Biotech plans a clinical trial in the first half of 2017
  • 15 Aug 2016 Moleculin Biotech intends to apply for accelerated approval pathway for Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top